Key Takeaways J&J expects 2026 revenues to rise over 5%, above the 4.6% consensus estimate.Innovative Medicine growth is likely to accelerate, driven by Darzalex, Tremfya and new oncology launches.MedTech momentum to build on new products like Shockwave C2 Aero and Tecnis intraocular lens.On its third-quarter earnings conference call on Oct. 14, Johnson & Johnson (JNJ) discussed its preliminary outlook for 2026. J&J said that the consensus estimates for 2026, for both the top and the bottom lines, are too l ...